ETON

Eton Pharmaceuticals, Inc.

$36.17 -1.57 (-4.16%) At close · Jul 8

Market Cap

$1.02B

27,392,358

Equibles Rating blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 16.9 · calm Equity put/call 0.86

Technical

price trend

Strong Buy

50 / 200-day cross No cross

Price vs 200-day avg +66%

above

Price vs 50-day avg +15%

above

RSI (14) 62

neutral

MACD trend Positive

52-week position 90%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +21%

trailing

6-month return +130%

trailing

YTD return +114%

this year

Relative strength +123%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $32 › 200d $22 — 50d above 200d

Institutional flow Accumulating

3 of 115 funds reported for Jun 30 · net +113 sh shares · +2 new

Insider flow Distributing

Net -$13.4M over 90 days · 100% sells

Short interest Rising

5.20% of float · ▲ +13.0% MoM · 4.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

115 holders — near 3-yr high, broad support

Squeeze score 76

high risk · 0–100

Fundamentals

Excellent

Revenue growth +105%

Y/Y

Gross margin 53%

contracting

Free cash flow $10.2M

Balance sheet $3.9M

net debt

Quant / Vol

risk profile

Very High

Volatility 54%

annualized · 1-yr

Max drawdown −36%

past year

ATR 4.4%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next

Next earnings call

Aug 11, 2026 Est · unconfirmed · in 5 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 14, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Guidance & track record what management promised — and delivered

Latest guidance · from the 8-K filed May 14, 2026

Revenue · full year 2026 at least $120M

prior FY $79.95M midpoint +50.1% Y/Y

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy

0 · 3 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+66% Bullish

Price vs 50-day avg

+15% Bullish

RSI (14)

62 Neutral

MACD trend

Positive Bullish

52-week position

90% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $32 › 200d $22 — 50d above 200d

Institutional flow Accumulating

3 of 115 funds reported for Jun 30 · net +113 sh shares · +2 new

Insider flow Distributing

Net -$13.4M over 90 days · 100% sells

Short interest Rising

5.20% of float · ▲ +13.0% MoM · 4.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

115 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $14 Now $36 · 90% 52-wk high $39

vs 200-day avg +66% vs 50-day avg +15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
Adjusted EBITDA non-GAAP	$5.7M	Q1 2026	—

product sales	$24.3M	Q1 2026	—
Adjusted EBITDA margin non-GAAP	24%	Q1 FY2026 call	—
active patients on therapy (GALZIN)	300	Q4 2025	—
basic non-GAAP EPS non-GAAP	$0.21	Q4 2025	—
fully diluted non-GAAP EPS non-GAAP	$0.19	Q4 2025	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ETON Eton Pharmaceuticals, Inc. this stock	$1.02B	+113.9%	+48.9%	—	5.2%
TAK Takeda Pharmaceutical Co Ltd	$53.04B	+7.4%	—	—	0.2%
GALDY Galderma Group AG/ADR	$51.02B	+4.9%	—	—	0.0%
JHPCY Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR	$45.13B	—	—	—	0.0%
HLN Haleon plc	$42.76B	-3.6%	—	—	0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

117

% held: 65.2%
Reported: 3 of 115
Top holder: Opaleye Management Inc.

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Rising

Shares short

1.4M

Days to cover: 4.1d
Change: +164.5K sh

View

Short Volume

Short vol %

57%

As of: Jul 9, 2026

Short Total

View

Fails to Deliver

FTD shares

15.6K

Value: $538.6K
As of: May 21, 2026

View

Off-Exchange

Off-exchange %

41.8%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$13.4M

Buyers / Sellers: 0 / 4

Buyers Sellers

View

Financials

Revenue (FY)

$80.0M

Net income (FY): $-4.6M

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Jun 30, 2026
This year: 15

View

Proposed Sales

Value

$9.0M

Shares: 251.8K
Filed: Jun 26, 2026

View

Exempt Offerings

Offering

$7.5M

Filed: Apr 8, 2020

View

Earnings & Events

Earnings Calls

Last call

Jun 4, 2026

View

Performance

	5D	20D	120D	MTD	YTD
ETON	-0.1%	+20.8%	+129.9%	-0.1%	+113.9%
SPY	-0.2%	+0.8%	+7.4%	-0.2%	+9.3%
vs SPY	+0.1%	+19.9%	+122.5%	+0.1%	+104.6%

Key facts CIK 1710340 CUSIP 29772L108 13F (30d) 4 filings 4 filers Visit website Investor relations

ETON

Price & Indicators

Technicals

Key metrics

Versus peers

At a glance

Performance